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Parkinson’s disease (PD) is the second most common neurodegenerative disorder. This
chronic, progressive disease is characterized by loss of dopaminergic (DA) neurons in
the substantia nigra pars compacta (SNpc) and the presence of cytoplasmic inclusions
called Lewy bodies (LBs) in surviving neurons. PD is attributed to a combination of
environment and genetic factors, but the precise underlying molecular mechanisms
remain elusive. Oxidative stress is generally recognized as one of the main causes of PD,
and excessive reactive oxygen species (ROS) can lead to DA neuron vulnerability and
eventual death. Several studies have demonstrated that small non-coding RNAs termed
microRNAs (miRNAs) can regulate oxidative stress in vitro and in vivo models of PD.
Relevant miRNAs involved in oxidative stress can prevent ROS-mediated damage to DA
neurons, suggesting that specific miRNAs may be putative targets for novel therapeutic
targets in PD.
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INTRODUCTION
PD is the most common degenerative movement disorder affecting 1–2% of individuals older
than 65 (de Lau and Breteler, 2006). It is clinically characterized by motor symptoms including
resting tremor, muscle rigidity, bradykinesia, and general postural instability. Obviously, the
patients of PD gradually suffer from severe motor and cognitive disability in the years after
diagnosis, which imposes a considerable burden on both families and society (Savitt et al.,
2006). In PD, the imbalance between ROS production and the antioxidant system results in
oxidative stress. Superoxide (O2−), hydrogen peroxide (H2O2), and the hydroxyl radical (OH•),
the main biologically ROS in mammalian cells can damage macromolecules including nucleic
acids, lipids and proteins, leading to dopaminergic (DA) neuron degeneration, and neuron
network dysfunction, ultimately progressing to PD (Sanders and Greenamyre, 2013). It is well
accepted that oxidative stress contributes to PD, and there is interest in understanding how
oxidative stress is exacerbated by the emerging regulators, microRNAs (miRNAs) via contributing
to the pathological processes which are responsible for oxidative stress like mitochondrial
dysfunction (Subramaniam and Chesselet, 2013), α-synuclein aggregation (Hsu et al., 2000),
neuroinflammation (Tansey et al., 2007), and dysregulation of the endogenous antioxidant system
(Buendia et al., 2016). microRNAs are highly conserved noncoding RNAs, ∼18–25 nucleotides in
length that can regulate protein expression either by translational inhibition or targeted mRNA
cleavage (Bartel, 2009; Guo et al., 2010). miRNA transcripts are produced in the nucleus and
then processed into hairpin RNA (pre-RNA) by the Drosha microprocessor complex. Exprotin-5
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transfers pre-RNA out of the nucleus for final processing
to mature RNA by the RNAase III enzyme Dicer. Mature
RNA forms the RNA-induced silencing complex (RISC) with
Argonaute (Ago) proteins, which can form sequence-specific
base-pairing with target mRNA, usually with the 3′-untranslated
region (UTR). The formation can regulate target gene expression
through mRNA degradation or translational inhibition, in which
polymorphisms in the 3′- UTR of target mRNA may play a
role (Ghanbari et al., 2016). Actually, one miRNA may have
multiple mRNA targets, so that it may involve in diverse
pathological processes. Meanwhile, the 3′-UTR of target mRNA
can be recognized by multiple miRNAs and they can alter
cellular responses via a coordinated network (Filipowicz et al.,
2008). It has recently been shown that miRNAs are involved
in different pathways to regulate cellular redox responses and
participate in the pathophysiological processes of PD (seen in
Figure 1). In this review, we will highlight the significant roles
of miRNAs in oxidative stress contributing to pathogenesis of PD
in models of PD.
miRNAs AND MITOCHONDRIAL
DYSFUNCTION
Oxidative phosphorylation is the main mechanism by which
energy (ATP) is produced to power neural activity (Sterky
and Larsson, 2008). However, when the normal function
of mitochondria is impaired, leakage of electrons from the
respiratory chain may directly promote ROS production,
eventually exacerbating neuronal dysfunction. Mitochondrial
dysfunction and reduced complex I activity are observed in
the SNpc and frontal cortex of PD patients (Parker et al.,
2008). Several studies have implied that miRNAs may serve
as potential biomarkers and provide a possible therapeutic
avenue to alleviate mitochondrial dysfunction in PD. It has
been reported that miR-124 is downregulated in DA neurons of
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced
mice and in MPP+(1-methyl-4-phenylpyridinium)-treated SH-
SY5Y cells, respectively. Conversely, miR-124 upregulation can
inhibit expression of the protein Bim, and reduce translocation
of its downstream protein Bax to mitochondria and lysosome,
thus suppressing mitochondria apoptotic signaling pathways
and normalizing the impaired autophagy process (Wang et al.,
2016). Gene mutations also can be blamed for mitochondrial
dysfunction (Ryan et al., 2015). Mutations in PARK7, the
encoding gene of protein DJ-1can cause autosomal recessive
PD characterized by decreased DJ-1 levels in the SNpc.
Numerous studies have demonstrated that DJ-1 can directly
bind to the subunits of complex I and maintain its activity
as an integral mitochondrial protein (Hayashi et al., 2009).
Mitochondrial morphology and dynamics are clearly damaged
in DJ-1-knockdown neurons (Irrcher et al., 2010). A recent
study indicated that miR-494 could increase oxidative stress-
induced neuronal lesions by inhibiting DJ-1 expression (Xiong
et al., 2014). Another study has proposed that reduced miR-
34b/c levels along with decreased expression of DJ-1 could
contribute to abnormal mitochondrial defects in the brain of
PD patients, which is confirmed in miR-34b/c-depleted cells.
However, miR-34b/c may modulate DJ-1 expression in an
indirect way and the specific mechanism needs to be further
clarified (Minones-Moyano et al., 2011). Mutation in leucine-
rich repeat kinase 2 (LRRK2) is another identifiable cause for
autosomal dominant PD. Increased LRRK2 protein levels can
compromise mitochondrial dynamics and integrity through a
fission protein, called dynamin-like protein (DLP1; Mortiboys
et al., 2010; Wang et al., 2012). Interestingly, miR-205 expression
is significantly downregulated in the brains of PD patients,
accompanied by elevated LRRK2 protein levels. Further studies
revealed that miR-205 could suppress LRRK2 protein expression
in primary neuron cultures by targeting the 3′-UTR of LRRK2
gene (Cho et al., 2013). Moreover, miRNAs exhibit a critical
role in inflammation-mediated mitochondrial dysfunction in
PD. Following treatment of SH-SY5Y cells with tumor necrosis
factor-α, increased miR-27a and miR-103 could suppress
expression of the functional units of complexI and higher levels of
miR-155 and miR-27a could result in mitochondrial defects and
oxidative stress via downregulating transcript levels of ATP5G3,
a subunit of complexV (Prajapati et al., 2015). In addition,
miR-7 has been found to stabilize mitochondrial membrane
potential via suppressing the expression of voltage-dependent
anion channel 1 (VDAC1), one constituent of the mitochondrial
permeability transition pore, which might be a potential target
for attenuating the impaired mitochondrial function in PD
(Chaudhuri et al., 2016).
miRNAs AND α-SYNUCLEIN
AGGREGATION
α-synuclein (α-Syn) is the main component of the LBs, and
its presence in these structures correlates with non-motor
manifestations of PD, including autonomic, sleep, and olfactory
dysfunction. Point mutations and multiplications in the SNCA
gene locus in familial PD, are directly associated with high
levels of α-Syn mRNA and proteins in the frontal cortex (Venda
et al., 2010). It is generally accepted that oxidative stress can
trigger the expression of α-Syn and increase its oligomerization
and fibrillization, subsequently aggravating its neurotoxicity. In
the contrast, aggregated α-syn species can impair mitochondrial
structure and inhibit complex I activity, thus promoting ROS
production (Hsu et al., 2000). In the course of PD, the two
processes form a vicious circle and accelerate progression of
the disease. Currently, it has been suggested the decreased level
of miR-7 and miR-214 possibly contributes to increased α-Syn
accumulation in the MPTP-induced model of PD (Junn et al.,
2009; Wang et al., 2015). Another study has further confirmed
that mir-7 and mir-153 could synergistically downregulate α-Syn
expression post-transcriptionally (Doxakis, 2010). Additionally,
one study has revealed that the decreased level of miR-34b/c
in specific brain areas of PD patients, including the amygdala,
frontal cortex, substantia nigra, and cerebellum, might contribute
to PD pathogenesis for losing its function of inhibiting α-
Syn expression (Kabaria et al., 2015b). miRNAs not only can
regulate α-Syn synthesis, but can also impair its degradation
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FIGURE 1 | Schematic model depicting the role of miRNAs regulating oxidative stress in PD. Activation steps are represented by solid lines and inhibitory
effects are represented by dashed lines.
pathway known as chaperone-mediated autophagy (CMA). CMA
pathway for removing exceptional α-Syn mainly includes two
proteins: lysosomal-associated membrane protein 2A (LAMP-
2A) and heat shock protein 70 (hsc70). It has been suggested
that increased miR-21, miR-224, and miR-373 in the SNpc could
inhibit LAMP-2A expression, while enhanced levels of miR-
26b, miR-106a, and miR-301b could suppress hsc70 expression,
resulting in α-Syn deposition by inhibiting its degradation
(Alvarez-Erviti et al., 2013). Furthermore, other studies have
demonstrated that miR-320a and miR-16-1 could promote
aberrant α-Syn accumulation by targeting hsc70 in PD (Li et al.,
2014; Zhang and Cheng, 2014).
miRNA AND THE ENDOGENOUS
ANTIOXIDANT SYSTEM
As an endogenous mechanism against oxidative stress, the
nuclear factor erythroid 2-related factor 2-antioxidant-response
element (Nrf2-ARE) pathway is deregulated as PD progresses
(Ramsey et al., 2007). It is primarily regulated by its inhibitory
protein -Kelch-like ECH-associated protein 1 (Keap1), which
sequesters Nrf2 in the cytoplasm and facilitates its proteasomal
degradation, maintaining a low level of Nrf2 in cytoplasm. Under
oxidative stress, the transcription factor may translocate to the
TABLE 1 | microRNAs profiling involved in oxidative stress in PD.
Human studies/
Experiment models
Upregulated
miRNAs
Downregulated
miRNAs
Rhythmic
miRNAs
Experiment models miR-494 miR-153
miR-142-5p
miR-124 miR-214
miR-7
miR-96-5p
miR-27a miR-103
miR-155
miR-153
PD patients miR-320a
miR-26b
miR-301b
miR-34b/c
miR-205
miR-21 miR-224
miR-373
miR-34b/c, miR-205 were both decreased in PD patients and experiment models, which
are highlighted.
nucleus and activate the expression of its downstream ARE such
as NADPH quinine oxidoreductase 1 (NQO-1), heme oxygenase-
1 (HO-1), superoxide dismutase (SOD), and glutathione (GSH),
etc (Satoh et al., 2006; Zhang et al., 2013). Treated with the
agonist of the Nrf2-ARE pathway, the nigrostriatal neurons
exhibit greater resistance to MPTP-induced neurotoxicity (Yang
et al., 2009). Brain-enriched miR-7 can repress Keap1 expression,
which leads to increased Nrf2 activity and upregulation of HO-1
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expression in SH-SY5Y cells (Kabaria et al., 2015a). Moreover,
it was found that DJ-1, the stabilizer of Nrf2 could upregulate
the level of SOD1 through activating the Erk1/2–Elk1 pathway
(Wang et al., 2011). Meanwhile, DJ-1 is the direct target of
miR-494 as aforementioned (Xiong et al., 2014), so decreasing
the level of miR-494 might protect neurons against oxidative
insult by promoting SOD1expression as well as attenuating
mitochondrial impairment. Furthermore, the Nrf2-ARE pathway
is directly regulated by various protein kinases like protein
kinase C (PKC) and glycogen synthase kinase 3 beta (GSK-3b)
or epigenetic factors like miRNAs and promoter methylation,
which are independent of Keap1 (Bryan et al., 2013). Recently,
it was reported that miR-153, miR-27a, miR-142-5p, and miR-
144 could directly downregulate Nrf2 expression in SH-SY5Y
neuronal cells, thereby deregulating the ARE/GSH pathway and
disturbing GSH homeostasis in the brain (Narasimhan et al.,
2012). GSH is the most indispensable free radical scavenger
in the central nervous system, and a decreased GSH/GSSG
ratio is considered as a pathogenic factor in PD. Rhythmic
expression of the cysteine transporter excitatory amino acid
carrier 1 (EAAC1), an important regulator of GSH synthesis,
is negatively regulated by miR-96-5p, which also displays a
diurnal rhythm. In addition, blocking miR-96-5p with an
inhibitor can increase the levels of EAAC1 and GSH, exerting a
neuroprotective effect against ROS in the mouse SN (Kinoshita
et al., 2014).
CONCLUSION
Although numerous studies have provided evidence that
miRNAs play a role in PD pathogenesis by regulating oxidative
stress, the field is still in its infancy. Actually, the causal factors
inducing oxidative stress in PD connect and interact with each
other rather than function independently, which make it difficult
to elucidate the function of related miRNAs totally. In addition,
accumulating evidences mainly confirmed from animal and cell
models, and related miRNA studies in PD patients are limited
to the difference expression in the brain (Table 1). To date, it
is not clear whether specific miRNAs can directly induce PD.
As the field matures, understanding how miRNAs can mediate
oxidative stress in PD could lead to the development of new PD
therapies.
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